- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
January 27th, 2005
Starpharma shares soared yesterday after the nanotechnology group confirmed that it had signed a strategic and potentially lucrative deal with The Dow Chemical Company.
Under the three-way deal, Starpharma's US-based subsidiary, Dendritic NanoTechnologies (DNT), will acquire Dow's extensive portfolio of patents covering dendrimer technology. It also gains the rights to revenue from Dow's already established licensing activities.
|Related News Press|
Nanotech Grants Options September 22nd, 2016
Arrowhead Pharmaceuticals to Present at Upcoming September Conferences September 1st, 2016
Industrial Nanotech, Inc. Provides Shareholder Update August 22nd, 2016
New nanomedicine approach aims to improve HIV drug therapies October 24th, 2016
Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016
Nanobiotix revenue for Q2 2016 July 14th, 2016